IQVIA and NVIDIA bring AI age into view

12 June 2025

Research services company IQVIA (NYSE: IQV) has unveiled new AI agents built using NVIDIA (Nasdaq: NVDA) technology that are designed to enhance workflows and accelerate insights for life sciences.

While IQVIA Healthcare-grade AI has previously been delivering insights for the life sciences industry across the asset life cycle, the company is confident that this recent collaboration with NVIDIA represents an exciting new phase as it advances the powerful future promised by agentic AI in a way that meets the unique needs of life sciences companies.

Bhavik Patel, president of IQVIA commercial solutions, said: “This is a pivotal opportunity to deliver the precise, efficient workflows and insights required by the modern life sciences industry backed by deep industry expertise and powerful technology partnerships.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK